Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paxceed
- Development stage
- Phase 2
- Lead developer
- Angiotech Pharmaceuticals
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Paxceed is a micellar formulation of paclitaxel developed by Angiotech Pharmaceuticals specifically for the treatment of rheumatoid arthritis (RA). It utilizes a polymeric micelle delivery system composed of PEG2000-b-PDLLA1333 to encapsulate paclitaxel, a small molecule microtubule stabilizer. This nanotechnology-based formulation was designed to avoid the hypersensitivity reactions associated with the Cremophor EL vehicle used in traditional oncology-grade paclitaxel (Taxol), making it more suitable for patients with immune-mediated diseases. In RA, Paxceed aims to inhibit the aggressive proliferation of synovial cells and the formation of pannus, which are key drivers of joint destruction. The drug reached Phase 2 clinical trials for patients with active RA who had failed standard disease-modifying antirheumatic drugs (DMARDs), though development was subsequently terminated.
- Brand names
- Paxceed
- Other names
- Micellar paclitaxelMicellar Paclitaxel for InjectionPTX-loaded PEG2000-b-PDLLA1333 micellar formulation
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on Paxceed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Paxceed.